WHITE PAPER
Placebo response in Psychiatry Trials - Truth or Myth
Mar 06, 2024
Download

IQVIA Team in India conducted an Advisory board involving four leading Psychiatrists on July 8, 2023, to address clinical trials in Psychiatric disorders.

  • The recent recognition of the global importance of mental disorders has put psychiatry firmly on the international health agenda.
  • The World Health Organization has estimated that neuropsychiatric disorders and suicide account for 12.7% of the global burden of disease.
  • Major depression, schizophrenia, bipolar affective disorder, alcohol misuse, and obsessive-compulsive disorder account for five of the 10 leading causes of disability in low- and middle-income countries.
  • There are currently promising psychiatric agents being developed to treat various mental disorders, including schizophrenia and major depressive disorder. These novel agents shed new light on brain functioning and show promise in improving the quality of life for patients suffering from psychiatric conditions.
  • While IQVIA conducts several global clinical trials in Psychiatry, India is sometimes overlooked on account of the perception of increased placebo response. The Advisory Board was used to discuss this issue and find remedial measures.
Contact Us